US Pharma MarketingA personalized mRNA therapy met two melanoma trial goals, the FDA cleared the first treatment for GSDIa, and Novo tests lower doses of its obesity pill.
Moderna and Merck’s cancer vaccine clears phase 3; Ultragenyx lands gene therapy nod
A personalized mRNA therapy met two melanoma trial goals, the FDA cleared the first treatment for GSDIa, and Novo tests lower doses of its obesity pill.
Source: PharmaVoice